Is MOTS-c Legal in Wisconsin?

What Is MOTS-c and Why Does Its Legal Status Matter?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid mitochondria-derived peptide first characterized in a 2015 paper by Lee et al. Published in Cell [1]. The peptide is encoded in mitochondrial DNA, not nuclear DNA, which makes it biologically unusual. Early research in mice showed that MOTS-c injections improved insulin sensitivity and reduced high-fat-diet-induced obesity [1].

Because MOTS-c acts on skeletal muscle metabolism and AMPK signaling pathways, it has attracted interest from researchers studying metabolic disease, aging, and exercise performance. That scientific interest is legitimate. The legal question, however, is separate from the scientific one.

Why Patients in Wisconsin Are Asking About This

Interest in peptide therapies has grown alongside the popularity of GLP-1 agonists and TRT. Patients who read about MOTS-c in longevity or biohacking communities often assume that because a peptide is "natural" or mitochondria-derived, it is automatically legal to purchase or use. That assumption is incorrect under U.S. Federal law.

Wisconsin has roughly 5.9 million residents and is served by dozens of compounding pharmacies licensed by the Wisconsin Pharmacy Examining Board [2]. None of those pharmacies can legally compound MOTS-c for patient use under current FDA rules, regardless of what a prescriber writes on a pad.

The Difference Between "Not Banned" and "Legal to Dispense"

A common misreading of pharmaceutical law treats silence as permission. Wisconsin has no statute that says "MOTS-c is illegal." But that silence does not mean a pharmacy can compound it or that a prescriber can order it for a patient. The FDA's framework for compounded drugs sets positive requirements: a substance must appear on the appropriate approved or nominated bulk list before a 503A or 503B pharmacy can use it. MOTS-c does not currently appear on either list [3].

Federal FDA Framework: The Rules That Actually Govern MOTS-c in Wisconsin

Federal law, not Wisconsin state law, is the controlling legal layer for MOTS-c. Understanding three specific regulatory categories tells you almost everything you need to know.

FDA-Approved New Drug Applications (NDAs) and BLAs

An FDA-approved drug has passed Phase I through Phase III trials and received a New Drug Application (NDA) or Biologics License Application (BLA) approval. MOTS-c has no NDA or BLA. No pharmaceutical sponsor has submitted one. This alone means MOTS-c cannot be marketed or sold as a drug in the United States by any route [4].

Section 503A Compounding Pharmacies

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) governs traditional compounding pharmacies that prepare individualized prescriptions for specific patients. These pharmacies may use bulk drug substances only if:

• The substance appears on the FDA's 503A bulk substances list (also called the "Category 1" list), or
• A nomination and review process is actively ongoing and the substance is not otherwise prohibited.

MOTS-c has not been nominated to the 503A list as of the date of this article's publication, nor does it appear on the list [3]. A 503A pharmacy in Madison, Milwaukee, or Green Bay cannot legally compound MOTS-c vials for a patient prescription.

Section 503B Outsourcing Facilities

Section 503B covers larger outsourcing facilities that can produce compounded drugs without patient-specific prescriptions and distribute them to healthcare facilities. The rules for bulk substance use are similarly restrictive. A substance must appear on the 503B bulk substances list or be under active review. MOTS-c is not on that list either [3].

The FDA's 2023 and 2024 guidance documents on bulk substance nominations made clear that peptides with no approved human use and no active nomination process cannot be used by outsourcing facilities [5].

Wisconsin State Pharmacy and Medical Practice Law

Wisconsin's Pharmacy Examining Board operates under Wisconsin Statute Chapter 450, which governs the practice of pharmacy in the state [2]. The Board can discipline a pharmacist for violating federal law, including for compounding a substance that federal rules prohibit. This means a Wisconsin pharmacist who compounds MOTS-c for a patient prescription faces both federal FDA enforcement exposure and potential state board discipline.

Wisconsin Medical Practice Act

The Wisconsin Medical Practice Act (Chapter 448) governs physician conduct [6]. A physician who writes a prescription for a substance that cannot legally be compounded or dispensed may face questions about prescription validity. While the Act does not list MOTS-c by name, writing a prescription that has no legal pathway to fulfillment is inconsistent with standard prescribing practices.

No Wisconsin-Specific Controlled Substance Scheduling

MOTS-c does not appear on Wisconsin's Controlled Substances Schedule (Wisconsin Statute Chapter 961) [7]. It is not listed as a Schedule I, II, III, IV, or V substance. This is the legal basis for the "not technically illegal in Wisconsin" statements that circulate online. Personal possession of MOTS-c for research purposes carries no criminal penalty under Wisconsin law as it currently reads.

But personal possession for self-administration is a different matter clinically and legally. Administering an unregulated, non-sterile, non-pharmacy-grade peptide to yourself carries serious health risks independent of the legal question.

The "Research Chemical" Gray Zone

Some vendors sell MOTS-c labeled "for research use only, not for human consumption." This label is common in the peptide market and creates a regulatory gray zone that deserves clear explanation, not just a dismissal.

What "Research Use Only" Actually Means

The FDA has stated in multiple warning letters that a "not for human use" label does not exempt a product from regulation if the vendor's marketing, customer communications, or product design make clear that human use is the intended purpose [8]. A vendor selling MOTS-c vials in sterile bacteriostatic water with dosing guides in milligrams per kilogram of body weight is effectively marketing a drug product to humans, regardless of what the label says.

Risks of Unregulated Peptide Sources

Research-grade peptides purchased outside a licensed pharmacy carry specific, documented risks:

• Contamination with bacterial endotoxins (lipopolysaccharides), which cause fever and sepsis if injected [9].
• Incorrect amino acid sequences or truncated peptides from low-quality synthesis.
• Inaccurate labeling of peptide concentration, potentially by a factor of 2x to 10x in either direction.
• No sterility testing. A 2022 analysis of commercially available research peptides found that 37% of tested samples failed USP sterility standards [9].

A patient who buys MOTS-c from an online research vendor and self-injects it in Wisconsin is not committing a criminal act under current Wisconsin law. That person is, however, assuming substantial health risk and acting outside any physician-supervised care relationship.

How MOTS-c Research Actually Works: What the Science Shows

Understanding the research field helps patients calibrate expectations. MOTS-c is genuinely interesting science. It is not, however, established clinical medicine for humans.

The 2015 Cell Paper: Where It Started

The foundational study by Lee et al. (2015), published in Cell, demonstrated that MOTS-c regulates glucose metabolism through the AMPK pathway in mouse skeletal muscle [1]. Mice receiving MOTS-c injections showed reduced fat accumulation on a high-fat diet and improved insulin sensitivity compared to controls. The paper generated significant attention in the aging and metabolism research community.

Human Data: Very Limited

As of early 2025, published human data on MOTS-c is sparse. A 2019 observational study in PNAS found that circulating MOTS-c levels in the blood declined with age and were lower in individuals with insulin resistance, suggesting a physiological role [10]. That is correlation, not an intervention trial.

No completed, peer-reviewed Phase I or Phase II clinical trial of exogenous MOTS-c administration in humans had been published as of this writing. ClinicalTrials.gov lists a small number of early investigational protocols, but none with published efficacy or safety endpoints.

The gap between mouse data and approved human therapy is large. The FDA's own drug approval statistics show that compounds with promising rodent metabolic data fail in human trials at a rate exceeding 90% across therapeutic categories [4].

Exercise Performance and Aging: Promising but Premature

Subsequent animal studies have examined MOTS-c in the context of exercise capacity and longevity. A 2019 paper in Nature Communications showed that MOTS-c levels increase in mouse plasma during exercise and that exogenous MOTS-c improved physical performance in aged mice [11]. This has led to significant lay-press coverage and interest from the athletic and longevity communities.

Those findings are hypothesis-generating. They do not constitute evidence sufficient to justify clinical use in humans, and no professional society guideline from the Endocrine Society, the American Association of Clinical Endocrinology, or any other major body recommends MOTS-c as a clinical intervention [12].

What a Legitimate Prescriber Can (and Cannot) Do in Wisconsin

Patients often approach telehealth platforms or local clinics hoping a physician can simply prescribe MOTS-c. Here is the accurate picture.

Prescriptions Require a Legal Dispensing Pathway

A valid prescription requires a pharmacy that can legally fill it. Because no licensed 503A or 503B pharmacy can currently compound MOTS-c, a prescription for MOTS-c has no legal fulfillment route in the United States. Writing such a prescription does not create legal access to a pharmacy-grade product.

Investigational New Drug (IND) Applications

The only legal pathway for a U.S. Physician to administer MOTS-c to a human patient is through an FDA-approved Investigational New Drug (IND) application [4]. This process requires submitting preclinical safety data, a study protocol, and IRB approval. It is used for academic or clinical research, not routine patient care. A Wisconsin physician would need to obtain their own IND or enroll patients in an existing approved IND study.

What Responsible Telehealth Platforms Will Tell You

A telehealth platform operating in compliance with federal and state law cannot prescribe or dispense compounded MOTS-c at this time. Platforms that claim otherwise are either misinformed or knowingly operating outside FDA guidance. The HealthRX medical team does not prescribe MOTS-c for patient use given the current regulatory status.

Regulatory Pathway to Future Legal Access

The situation could change. Here is how.

503A Bulk Substance Nomination Process

Any pharmacist, physician, or patient advocate can submit a nomination to the FDA's 503A Bulks List [3]. The nomination must include evidence of the substance's clinical usefulness, safety profile, and compounding rationale. If MOTS-c is nominated and the FDA places it on the Category 1 list after review, 503A pharmacies would then be permitted to compound it for individual patient prescriptions.

As of January 2025, no active public nomination for MOTS-c appears in the FDA docket.

IND-Based Clinical Trials

A pharmaceutical company or academic institution could file an IND and conduct Phase I/II trials in humans. Positive safety data from a Phase I study would not automatically make MOTS-c legally available for general prescribing, but it would establish a safety record that could support future NDA submission or 503A nomination.

Monitoring for Changes

Patients interested in MOTS-c therapy should monitor the FDA's bulk substances nomination dockets (available at FDA.gov) and ClinicalTrials.gov for any approved human trials that offer enrollment opportunities [4].

Practical Guidance for Wisconsin Residents

If You Are Considering MOTS-c

Consult a licensed physician before purchasing or using any peptide product. A physician can review your metabolic health, discuss evidence-based alternatives that are currently legal and supported by human trial data, and help you assess whether enrolling in a clinical trial makes sense for your situation.

Evidence-based options for metabolic health, insulin sensitivity, and weight management do exist with documented human safety and efficacy data. Semaglutide, for example, produced 14.9% mean body weight loss at 68 weeks in the STEP-1 trial (N=1,961) versus 2.4% in the placebo group (P<0.001) [13]. Tirzepatide produced up to 22.5% weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539) (P<0.001) [14]. These options have approved status, pharmacy dispensing pathways, and established safety profiles.

If You Already Have MOTS-c

Possession of MOTS-c purchased from a research vendor is not a criminal offense under current Wisconsin law. Self-injecting it is not advisable given the contamination risks described earlier. If you have questions about your current peptide use, speak with a physician without fear that honest disclosure will result in legal consequences to you as a patient.

Finding a Wisconsin Provider for Peptide-Adjacent Therapies

The Wisconsin Medical Society maintains a provider directory [6]. Hormone and metabolic health clinics in Milwaukee, Madison, Green Bay, and other population centers may be able to offer legal, physician-supervised therapies that address underlying goals similar to those driving interest in MOTS-c.

Summary of Key Legal Points

The legal picture for MOTS-c in Wisconsin reduces to five specific facts:

1. MOTS-c is not FDA-approved for any human indication.
2. MOTS-c is not on the FDA's 503A or 503B bulk substances lists as of January 2025.
3. No Wisconsin statute schedules MOTS-c as a controlled substance.
4. Licensed Wisconsin pharmacies cannot legally compound MOTS-c for patient prescriptions under current federal law.
5. Legal human administration in Wisconsin requires an FDA-approved IND protocol.

The Endocrine Society's position on unapproved peptide therapies states that "patients should be informed when therapies lack sufficient evidence from adequately powered clinical trials, and prescribers should not provide access to substances through channels that circumvent regulatory oversight" [12].

Patients in Wisconsin who want peptide-based metabolic therapies should ask their provider specifically which FDA approval category applies to any recommended substance and which pharmacy will fill the prescription, verified as a licensed 503A or 503B facility.